NCT04721106 2026-02-10
Korea Post Marketing Surveillance (PMS) Study of Vizimpro
Pfizer
Completed
Clinical Trials
9 trialsNCT03810807 2025-12-23
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT04504071 2025-09-08
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations
Shanghai Chest Hospital
Phase 2 Active not recruiting
NCT02039336 2025-07-08
M13DAP
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT04027647 2025-06-12
Phase 2 Study of Dacomitinib in NSCLC
National Cancer Centre, Singapore
Phase 2 Active not recruiting
NCT04946968 2025-06-11
Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers
National Cancer Centre, Singapore
Phase 2 Active not recruiting
NCT04155541 2025-05-23
Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)
Pfizer
Completed
NCT03755102 2025-05-15
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed